Research programme: atopic dermatitis antibody therapeutics - Generate Biomedicines
Latest Information Update: 17 Jan 2025
Price :
$50 *
At a glance
- Originator Generate Biomedicines
- Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action OX40 ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Atopic dermatitis
Most Recent Events
- 06 Oct 2024 Early research in Atopic dermatitis in USA (Parenteral) prior to October 2024 (Generate Biomedicines Pipeline, October 2024)